Tropisetron, a New 5-HT3-Receptor Antagonist, in the Prevention of Radiation-Induced Nausea, Vomiting and Diarrhoea

Sorbe, Bengt; Berglind, Anne-Marie

doi:10.2165/00003495-199200433-00008

Cited by 23 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the most appropriate dose remains to be determined, the antiemetic efficacy, safety, and tolerability observed with dolasetron mesilate in this trial were consistent with results obtained with other 5-HT3 receptor antagonists in similar trials [12][13][14]16]. Our data demonstrate the effectiveness of dolasetron in controlling emesis in patients undergoing emetogenic cancer treatments.…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients

Bey

Wilkinson

Resbeut

et al. 1996

Support Care Cancer

View full text Add to dashboard Cite

The aim of this work was to measure the safety and efficacy of single i.v. doses of dolasetron mesilate for the control of emesis caused by single high-dose (at least 6 Gy) radiotherapy to the upper abdomen. The double-blind, placebo-controlled, multicenter study stratified patients on the basis of being naive or nonnaive to radiotherapy. Patients with or without a history of previous chemotherapy were enrolled. Patients were randomized to receive placebo or 0.3, 0.6, or 1.2 mg/kg dolasetron mesilate 30 min before radiotherapy, then monitored for 24 h. Antiemetic efficacy was assessed from the time to the first emetic episode or rescue, from whether there was a complete response (0 emetic episodes /no rescue medication) or a complete-plus-major response (0-2 emetic episodes/no rescue medication), from the severity of nausea (rated by patients and the investigator), and from the investigator's assessment of efficacy. Fifty patients completed the study (owing to changing medical practice, enrollment objectives were not met; consequently, no significant linear dose trend was expected). Pooled dolasetron was superior to the placebo in its effect on the time to first emesis or rescue in radiotherapy-nonnaive patients (P = 0.015). Dolasetron was statistically superior to the placebo in the overall population on the basis of a complete plus major response: 54%, 100%, 93%, and 83% for the placebo and 0.3-, 0.6-, and 1.2-mg/kg doses respectively (P = 0.002). The low response in the highest dose group may be due to an imbalance in the number of chemotherapy-nonnaive patients in that group. Dolasetron was superior to the placebo on the basis of nausea assessed by the investigator (P = 0.024) and administration of rescue medication (P = 0.006). Complete response at the 0.3-mg/ kg dose was superior to results with the placebo (P = 0.050). Treatment-related adverse events were rare, mild to moderate in intensity, and evenly distributed across the four groups. Overall, dolasetron mesilate was effective and well-tolerated in the control of single, high-dose radiotherapy-induced emesis.

show abstract

Section: Discussionsupporting

confidence: 86%

“…The majority of adverse events were mild to moderate in intensity. Headache, which is associated with the use of 5-HT3 receptor antagonists in cancer chemotherapy [2,4,5,8,[11][12][13][14]16], was seen in 1/37 (2.7%) patients treated with dolasetron in this study. Vital signs were not consistently altered by study medication.…”

Section: Discussionmentioning

confidence: 77%

A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients

Bey

Wilkinson

Resbeut

et al. 1996

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…There have been no reported drug interactions with haloperidol, droperidol or benzodiazepines. Adverse events occurred more frequently during use of higher doses that are administered to chemotherapy patients as compared to the lower doses given to PONV patients [89,99,100,106]. Acute, reversible EGG changes affecting PR and QTc prolongation and QRS widening have been reported in clinical trials.…”

Section: -Ht 3 Ra Adverse Reactionsmentioning

confidence: 99%

Safety and efficacy of commonly used antiemetics

Hendren

Aponte-Feliciano

Kovac³

2015

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

The key to providing relief for patients suffering from nausea and vomiting is to consider multiple drugs to approach the nausea in a systematic way. Anesthesiologists identify patients who are at high risk of nausea and vomiting based on physical characteristics and surgical procedures. Oncologists treat nausea based on the prescribed chemotherapeutics regimen and known risk of emesis while palliative care physicians and others balance the etiology of the nausea while optimizing patients other co morbid conditions.

show abstract

“…Existe poca literatura referente al uso de tropisetrón en nausea y vómitos radioinducidos 15,16 . Otras publicaciones han comparado granisetrón con metoclopramida.…”

Section: Antagonistas De La 5-ht3unclassified

Protección gastrointestinal y antieméticos en radioterapia: II. Antieméticos

Vázquez

2004

Oncología (Barc.)

View full text Add to dashboard Cite

Tropisetron, a New 5-HT3-Receptor Antagonist, in the Prevention of Radiation-Induced Nausea, Vomiting and Diarrhoea

Cited by 23 publications

References 5 publications

A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients

A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients

Safety and efficacy of commonly used antiemetics

Protección gastrointestinal y antieméticos en radioterapia: II. Antieméticos

Contact Info

Product

Resources

About